Weekly Investment Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)

A number of firms have modified their ratings and price targets on shares of BioMarin Pharmaceutical (NASDAQ: BMRN) recently:

• 3/3/2026 – BioMarin Pharmaceutical had its price target raised by Barclays PLC from $80.00 to $105.00. They now have an “overweight” rating on the stock.
• 3/2/2026 – BioMarin Pharmaceutical was given a new $105.00 price target by Loop Capital.
• 2/26/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $98.00 to $104.00. They now have a “buy” rating on the stock.
• 2/25/2026 – BioMarin Pharmaceutical had its price target raised by Sanford C. Bernstein from $90.00 to $94.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – BioMarin Pharmaceutical had its price target lowered by Guggenheim from $106.00 to $86.00. They now have a “buy” rating on the stock.
• 2/25/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $60.00 to $55.00. They now have a “neutral” rating on the stock.
• 2/24/2026 – BioMarin Pharmaceutical was given a new $68.00 price target by Stifel Nicolaus.
• 2/24/2026 – BioMarin Pharmaceutical had its price target lowered by Oppenheimer Holdings, Inc. from $98.00 to $95.00. They now have an “outperform” rating on the stock.
• 2/18/2026 – BioMarin Pharmaceutical had its price target raised by Wells Fargo & Company from $70.00 to $75.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – BioMarin Pharmaceutical had its price target lowered by Piper Sandler from $122.00 to $84.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – BioMarin Pharmaceutical is now covered by Barclays PLC. They set an “overweight” rating and a $80.00 price target on the stock.
• 1/20/2026 – BioMarin Pharmaceutical was upgraded by Canaccord Genuity Group Inc. from “hold” to “buy”. They now have a $98.00 price target on the stock, up from $84.00.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.